| P2093 | author name string | Ankur Jindal | |
| | Rakesh Kumar Jagdish | |
| P2860 | cites work | Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway | Q22003738 |
| | Branched-chain amino acids for people with hepatic encephalopathy | Q24187134 |
| | Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People | Q24633789 |
| | Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation | Q26996234 |
| | Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling | Q28307009 |
| | Ammonia metabolism and hyperammonemic disorders | Q30903469 |
| | Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation | Q33624851 |
| | Nutrition and exercise in the management of liver cirrhosis | Q33780141 |
| | Linking intestinal homeostasis and liver disease | Q33828940 |
| | Clinical relevance of sarcopenia in patients with cirrhosis | Q33845474 |
| | Alcohol-induced autophagy contributes to loss in skeletal muscle mass | Q33878885 |
| | Frailty predicts waitlist mortality in liver transplant candidates | Q33934820 |
| | Factors associated with poor health-related quality of life of patients with cirrhosis | Q33935013 |
| | Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? | Q33970445 |
| | The key role of anaplerosis and cataplerosis for citric acid cycle function. | Q34135762 |
| | The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety | Q34306414 |
| | Ammonia production by human faecal bacteria, and the enumeration, isolation and characterization of bacteria capable of growth on peptides and amino acids | Q34546084 |
| | Hyperammonemic encephalopathy | Q34629212 |
| | Muscle mass predicts outcomes following liver transplantation | Q35246800 |
| | Sarcopenia: effects on body composition and function | Q35590167 |
| | Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis | Q35637935 |
| | Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. | Q36312414 |
| | Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis | Q36752026 |
| | Hyperammonemia results in reduced muscle function independent of muscle mass. | Q37148740 |
| | Pathogenetic mechanisms of hepatic encephalopathy | Q37217096 |
| | Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism | Q37318200 |
| | Branched-chain amino acids in liver diseases | Q37334109 |
| | Interorgan ammonia trafficking in liver disease | Q37344747 |
| | Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation | Q37408216 |
| | Interorgan ammonia metabolism in liver failure: the basis of current and future therapies | Q37776748 |
| | Chronic low-grade inflammation and age-related sarcopenia. | Q37959664 |
| | Exercise capacity and muscle strength in patients with cirrhosis. | Q37964614 |
| | Ammonia-lowering strategies for the treatment of hepatic encephalopathy. | Q38032730 |
| | A current review of the diagnostic and treatment strategies of hepatic encephalopathy | Q38058329 |
| | Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. | Q38062787 |
| | Myostatin/activin pathway antagonism: molecular basis and therapeutic potential | Q38110659 |
| | Interference between concurrent resistance and endurance exercise: molecular bases and the role of individual training variables | Q38204299 |
| | A review of resistance training-induced changes in skeletal muscle protein synthesis and their contribution to hypertrophy | Q38367638 |
| | The Role of Sarcopenia and Frailty in Hepatic Encephalopathy Management | Q38551212 |
| | Recent advances in understanding renal ammonia metabolism and transport | Q38883387 |
| | The integrated stress response. | Q38954583 |
| | Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement | Q39212291 |
| | Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial | Q40376778 |
| | Malabsorption and nutritional abnormalities in patients with liver cirrhosis. | Q41196259 |
| | Sarcopenia impairs prognosis of patients with liver cirrhosis | Q41639725 |
| | Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation | Q42228448 |
| | Exocrine pancreatic insufficiency and chronic pancreatitis in chronic alcoholic liver disease: coincidence or shared toxicity? | Q42653544 |
| | Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis | Q42707372 |
| | Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. | Q42732353 |
| | Reduced mitochondrial adenosine triphosphate synthesis in skeletal muscle in patients with Child-Pugh class B and C cirrhosis | Q43657666 |
| | Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis | Q44408638 |
| | Sources of oxygen radicals in brain in acute ammonia intoxication in vivo | Q44528987 |
| | Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. | Q45143194 |
| | Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. | Q46004774 |
| | Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. | Q46473191 |
| | Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis | Q46964120 |
| | Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis | Q47104014 |
| | Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis | Q47106695 |
| | Myostatin and beyond in cirrhosis: all roads lead to sarcopenia | Q47172232 |
| | Branched-chain amino acid supplementation in treatment of liver cirrhosis: Updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation | Q48172346 |
| | Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study | Q48260788 |
| | Protein energy malnutrition predicts complications in liver cirrhosis | Q48577176 |
| | Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats. | Q48909759 |
| | Taste perception in cirrhosis: Its relationship to circulating micronutrients and food preferences | Q50947915 |
| | Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. | Q51138513 |
| | Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. | Q52260548 |
| | Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. | Q53076240 |
| | Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. | Q53139960 |
| | [Testosterone treatment for patients with sarcopenia and liver cirrhosis]. | Q53760328 |
| | Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. | Q54416812 |
| | Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma | Q57314872 |
| | Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis | Q57314875 |
| | Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value | Q57314883 |
| | Evolution of sarcopenia research | Q57717404 |
| | Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score | Q58125434 |
| | Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis | Q58817415 |
| | Low testosterone levels as an independent predictor of mortality in men with chronic liver disease | Q62978474 |
| | Skeletal muscle and whole-body protein turnover in cirrhosis | Q68470747 |
| | Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception | Q70501837 |
| | Hypothalamic‐pituitary‐testicular function in end‐stage non‐alcoholic liver disease before and after liver transplantation | Q71808416 |
| | Long-term nutritional assessment and quality of life in patients with cirrhosis taking a late evening snack | Q79919496 |
| | Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver | Q81229899 |
| | Myostatin inhibits myosatellite cell proliferation and consequently activates differentiation: evidence for endocrine-regulated transcript processing | Q84750522 |
| | Liver transplantation arrests and reverses muscle wasting | Q86450680 |
| | Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial | Q87686617 |
| | Exercise in cirrhosis: Translating evidence and experience to practice | Q89379728 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 3 | |
| P921 | main subject | hepatic encephalopathy | Q642548 |
| | sarcopenia | Q1787939 |
| P304 | page(s) | 270-279 | |
| P577 | publication date | 2019-04-22 | |
| | 2019-09-01 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Sarcopenia: Ammonia metabolism and hepatic encephalopathy | |
| P478 | volume | 25 | |